New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:42 EDTAHS, CPHD, CLDX, IART, BIOS, USPH, PBTH, ARNA, DXCM, INSMOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 12 at 7:45 am; not all company presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:02 EDTARNAArena reports lorcaserin combo doubles weight loss in study
Subscribe for More Information
09:50 EDTARNAArena Pharmaceuticals shares should go higher today, says Piper Jaffray
Subscribe for More Information
09:47 EDTARNAArena Pharmaceuticals says BELVIQ U.S. quarterly sales $16.8M
Arena Pharmaceuticals disclosed that Eisai reported net sales of BELVIQ in the United States for the quarter ended September 30 of approximately $16.8M. Eisai markets and distributes BELVIQ in the United States under a marketing and supply agreement with Arena.
October 29, 2014
08:18 EDTARNAArena press release lacking key data, TheStreet's Feuerstein says
Subscribe for More Information
October 28, 2014
18:25 EDTARNAArena Pharmaceuticals, Eisai study meets primary safety objective
Eisai and Arena Pharmaceuticals announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl. The results of the investigational study demonstrate that the short-term combination of lorcaserin plus phentermine does not appear to be associated with an exacerbation in the proportion of pre-specified adverse events compared to therapy with lorcaserin alone. The coadministration of lorcaserin and phentermine for weight management is investigational. The efficacy and safety of coadministration of lorcaserin and other weight loss products such as phentermine have not been established.
07:22 EDTCPHDCepheid to collaborate with FIND and Rutgers for novel tuberculosis test
Cepheid, FIND, and Rutgers New Jersey Medical School, will collaborate to develop Xpert MTB/RIF Ultra, a next-generation test for Mycobacterium tuberculosis with increased sensitivity to aid in detection of patients with smear-negative TB, which is often associated with HIV co-infection. The collaboration is also receiving additional support from the National Institute of Allergy and Infectious Diseases at the NIH. Xpert MTB/RIF Ultra is expected to be available to the HBDC market in 1H16.
October 20, 2014
09:36 EDTCLDXActive equity options trading on open
Subscribe for More Information
09:27 EDTDXCMDexCom announces Dexcom SHARE FDA approval
Dexcom (DXCM) announced that it has received U.S. Food and Drug Administration approval for its CGM remote mobile communications device, Dexcom SHARE. With Dexcom SHARE, parents and personal caregivers can monitor a person's glucose data from a remote location via an Apple (AAPL) iPhone, or iPod touch.
October 16, 2014
17:35 EDTCPHDCepheid 'well positioned' to address Ebola
Subscribe for More Information
17:28 EDTCPHDCepheid sees Q4 adjusted EPS 2c-4c, may not compare to consensus (9c)
Subscribe for More Information
16:11 EDTCPHDCepheid sees FY14 adjusted EPS 11c-13c, may not compare to consensus (52c)
Subscribe for More Information
16:09 EDTCPHDCepheid reports Q3 EPS ex-items 6c, consensus (16c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use